Integer (NYSE:ITGR) Sets New 52-Week High – Should You Buy?

Integer Holdings Co. (NYSE:ITGR)’s stock price reached a new 52-week high during trading on Tuesday . The stock traded as high as $144.22 and last traded at $143.22, with a volume of 5118 shares changing hands. The stock had previously closed at $141.00.

Analyst Upgrades and Downgrades

ITGR has been the topic of several research analyst reports. Bank of America raised their price target on shares of Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, October 1st. Piper Sandler reissued an “overweight” rating and set a $140.00 target price (up from $125.00) on shares of Integer in a research report on Friday, October 25th. Wells Fargo & Company restated an “overweight” rating and set a $160.00 price target on shares of Integer in a research note on Tuesday, December 3rd. Benchmark raised their price objective on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Finally, Truist Financial lifted their price objective on Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $145.44.

Integer Stock Performance

The stock has a fifty day moving average price of $136.68 and a 200-day moving average price of $129.24. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $4.74 billion, a price-to-earnings ratio of 43.63, a PEG ratio of 1.82 and a beta of 1.12.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm had revenue of $431.42 million during the quarter, compared to analyst estimates of $440.59 million. During the same period in the prior year, the company posted $1.27 earnings per share. The business’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, analysts anticipate that Integer Holdings Co. will post 5.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Integer

A number of hedge funds have recently made changes to their positions in ITGR. Contravisory Investment Management Inc. increased its holdings in shares of Integer by 55.9% during the third quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 80 shares in the last quarter. Huntington National Bank increased its holdings in Integer by 8,933.3% during the 3rd quarter. Huntington National Bank now owns 271 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 268 shares in the last quarter. R Squared Ltd acquired a new stake in Integer during the 4th quarter valued at $44,000. Versant Capital Management Inc increased its holdings in Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 183 shares in the last quarter. Finally, GAMMA Investing LLC raised its position in Integer by 74.1% in the 3rd quarter. GAMMA Investing LLC now owns 653 shares of the medical equipment provider’s stock valued at $85,000 after purchasing an additional 278 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.